Analysts positive on US prospects for tivozanib but data request weighs on Aveo stock
This article was originally published in Scrip
It's hard to say whether investors were reacting more to Aveo Oncology's larger net loss or news that the US FDA had asked for more data on overall survival rates versus Nexavar (sorafenib) for the US company's Phase III kidney cancer drug and lead product candidate tivozanib, but the firm's stock price fell 26.8% when it announced second quarter 2012 earnings on 2 August.
You may also be interested in...
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
When the US FDA approved Olumiant (baricitinib) for RA, it insisted on a lower dose because of fears of blood clots. Now that an NIH trial has shown that the product plus Gilead’s Veklury (remdesivir) provided a statistically significant reduction in time to recovery versus remdesivir alone for hospitalized COVID patients, Olumaint may get an emergency use authorization from FDA to treat a condition that itself causes blood clots. That doesn't mean the black box is going away; it's just a reminder that there is as much magic and mystery to medicine sometimes as there is science.
Private Company Edition: Neogene, Escient, ESCAPE, Resolution and Attralus raised a combined $320m in venture capital rounds. Also, large Recursion round could double the size of its pipeline, Korro Bio raised $91.5m and Flagship launched Generate Biomedicines.